Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy

Variable

All

Fazekas score

Patients

0–2

3–6

0–5

6

% patients (n)

100% (45)

57% (26)

43% (20)

93% (43)

7% (3)

Age (years)

 Median

60.5

54.5

65.5

59.0

72.0

 Range

35–82

35–74

46–82

35–82

70–82

 ≤ 65

71.7%

88%

50%

77%

0%

Baseline KPS

 Median

85

90

80

80

80

 70–80

50%

44%

65%

51%

100%

 90–100

50%

56%

35%

49%

0%

Highest educationa

 Median

13

13

13

13

13

 Range

11–13

11–13

11–13

11–13

12–13

Baseline MoCA

 Median

27.5

27.5

27.5

28

26.0

 Range

20–30

20–30

20–30

20–30

20–30

Metastases (no.)

 Median

3

3.5

2.5

3

1

 Range

1–10

1–10

1–10

1–10

1–3

Volume of metastases (cm3)

 Mean

4.1

5.0

3.0

4.0

5.2

Peritumoral edemab (cm3)

 Mean

38.4

38.1

38.9

38.4

39.7

Intracranial volume (cm3)

 Mean

1531

1524

1542

1530

1557

WMH volume (cm3)

 Mean

8.0

1.8

16.0

5.0

50.4

  1. KPS Karnofsky performance status, MoCA Montreal Cognitive Assessment
  2. a13 = any post-secondary education
  3. bExcludes volume of metastases